Skip to content
Screener

ImmunityBio, Inc. IBRX Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$207M+6.7%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$22.53M+3.2%
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
$3.27M+3.0%
UroGen Pharma logo
UroGen PharmaURGN
$684K+2.4%
CG Oncology logo
CG OncologyCGON
$985K+242%
Immunome logo
ImmunomeIMNM
$152K

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$8.1B+247%
Enterprise value$8.34B+233%
P/S57.4×+16.2×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 7:37 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001326110-26-000059
Line itemClassificationMarch 31, 2026December 31, 2025
Total lease assets (including amounts with related parties)$33,290$33,281
Liabilities
Current:
Operating lease liabilities (including amounts with related parties)Operating lease liabilities$7,626$7,535
Finance lease liabilitiesAccrued expenses and other liabilities5352
Noncurrent:
Operating lease liabilities (including amounts with related parties)Operating lease liabilities, less current portion33,14733,447
Finance lease liabilitiesOther liabilities213227

ITEM 1. FINANCIAL STATEMENTS.

FAQ

What is ImmunityBio, Inc.'s operating lease liabilities (current)?
ImmunityBio, Inc. (IBRX) reported operating lease liabilities (current) of $7.63M in Q1 2026.
How has ImmunityBio, Inc.'s operating lease liabilities (current) changed year-over-year?
ImmunityBio, Inc.'s operating lease liabilities (current) increased by 2.2% year-over-year, from $7.46M to $7.63M.
What is the long-term trend for ImmunityBio, Inc.'s operating lease liabilities (current)?
Over 5 years (2020 to 2025), ImmunityBio, Inc.'s operating lease liabilities (current) has grown at a 8.5% compound annual growth rate (CAGR), from $5.02M to $7.54M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about ImmunityBio, Inc.'s operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude